Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Rexaceract

Source date not recordedAnalyse record ↗

Investigational GCase modulator being developed for Parkinson's disease with or without a GBA1 mutation.

Modality
oral brain-penetrant small-molecule GCase allosteric modulator
Availability (US)
Phase 2 IND authorized; company was preparing to initiate Phase 2 as of August 11, 2026, following Phase 1b
Biomarkers
GCase target engagement; CSF glucosylsphingosine; DOPA decarboxylase; MDS-UPDRS exploratory measures
Hallmark targeted
loss of proteostasis, disabled autophagy, mitochondrial dysfunction
Kind
investigational drug
Clinical trials
Australian Phase 1b and open-label extension in Parkinson's disease; planned multinational Phase 2a in early Parkinson's disease with or without a GBA1 mutation